A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00543712
Recruitment Status :
(Efficacy not evident in this population.)
This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up to 90 patients with confirmed chondrosarcoma will be enrolled.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Ability to understand and willingness to sign a written informed consent document
Age ≥ 18 years
Histologic diagnosis of chondrosarcoma, verifiable after enrollment
Previously treated or incurable disease without options for standard of care therapy
ECOG performance status of 0-2
Life expectancy of > 3 months
For patients of reproductive potential (males and females), use of reliable means for contraception (e.g., contraceptive pill, intrauterine device [IUD], physical barrier) throughout the trial and for 1 year following their final exposure to study treatment
Systemic therapy or radiotherapy within 4 weeks prior to Day 1
Prior therapy with agents targeting the DR5 apoptosis pathway
Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to Day 1, or anticipation of need for major surgical procedure during the course of the study
Other invasive malignancies within 5 years prior to Day 1
Known active brain metastases
Uncontrolled intercurrent illness, including but not limited to ongoing or active infection requiring parenteral antibiotics at enrollment
Clinically significant, symptomatic cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia, Grade II or greater peripheral vascular disease, or history of major heart surgery within 6 months of Day 1, or any situation that would likely limit compliance with study requirements
Known to be positive for hepatitis C or hepatitis B surface antigen
History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications
Use of anticoagulation therapy
Participation in clinical trials or undergoing other investigational procedures within 30 days prior to Day 1
Pregnancy or breast feeding
Known sensitivity to any of the products administered during the study
Any disorder that compromises the ability of the patient to give written informed consent and/or comply with study procedures